LD-2 disclosure · 4th Quarter - Report
INTELLIA THERAPEUTICS
Client
- Description
- biotechnology company
- Location
- Massachusetts · United States of America
Registrant
- Description
- lobbying firm
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
1 issueHealth Issues
Education and advocacy related to genome editing technology. Education around COVID-19 therapies. H.R.3, Lower Drug Costs Now Act of 2019. S.2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. H.R.1425, Patient Protection and Affordable Care Enhancement Act. FY2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.7614), FY2021 Consolidated Appropriations Act (H.R.7617), H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act. H.R.133, Making consolidated appropriations for the fiscal year ending September 30, 2021, providing coronavirus emergency response and relief, and for other purposes (P.L.116-260).
LobbyistsMATHEW LAPINSKI · MARC NUMEDAHL · KATHERINE DAPPER · JASON BENJAMIN VAN PELT · SHAY MICHAEL HANCOCK · JASON GLEASON
TargetedSENATE · HOUSE OF REPRESENTATIVES · Food & Drug Administration (FDA)